Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
Objective: Evaluate if patients fulfill the recently developed “5-2-1” screening criteria for advanced Parkinson’s Disease (APD)[1] prior to treatment with levodopa-carbidopa intestinal gel (LCIG) and…High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy
Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease duration on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease
Objective: To determine whether α-synuclein concentrations in the cell membrane and cytoplasm of erythrocytes are altered in PD patients and to evaluate their potential role…GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease
Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease
Objective: Evaluating effectiveness of sublingual Atropine 1% ophthalmic solution for treatment of sialorrhea in Parkinson’s disease. Background: Sialorrhea is common non-motor symptom of Parkinson’s disease.…Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data
Objective: To evaluate the opicapone (OPC) associated patient’s odds ratio (OR) in relative OFF-time reduction. Background: OPC, a once-daily COMT inhibitor, proved effective in the…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results
Objective: The efficacy of isradipine to slow progression of disability in de novo PD participants. Background: There remains no proven therapy to slow progression of…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 217
- Next Page »